Harrow, Inc. (HROW): Cost of Revenue
$67.93M
Year ended 2025-12-31
$73.64M
Trailing 12 months to 2026-06-30
+38.8%
3-year compound annual growth
+36.3%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $67.93M | +38.0% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $49.24M | +24.2% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $39.64M | +56.2% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $25.38M | +39.4% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $18.21M | +25.9% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $14.46M | -13.6% | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | $16.75M | +1.4% | 2021-03-08, From 2019-01-01 |
| 2018-12-31 | $16.52M | +22.3% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $13.51M | n/a | 2019-03-12, From 2017-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Harrow, Inc. (HROW) | 2025-12-31 | $67.93M | +38.0% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $113.25M | +50.1% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $100.07M | +19.2% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $22.09M | +628.0% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $39.46M | -37.5% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $58.16M | -9.7% |
| MannKind Corp (MNKD) | 2025-12-31 | $26.80M | +53.8% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $36.70M | +91.8% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $124.03M | -11.8% |
Compare HROW, SDGR, EOLS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗